Pyrotinib, an irreversible pan-ErbB inhibitor, combined with capecitabine can be considered as an alternative treatment option for patients with HER2-positive metastatic BC after trastuzumab and chemotherapy [20]. Here, ERBB2 is linked to breast cancer.